한글목차

바이러스 벡터 및 플라스미드 DNA 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 13억 8,000만 달러에서 2026년에는 14억 7,000만 달러에 이르고, CAGR 6.2%로 성장할 전망입니다. 지난 수년간의 성장은 바이러스 벡터 공급 제한, 연구용 플라스미드 DNA에 대한 의존도, 유전자 치료제 파이프라인 증가, 바이오의약품 연구개발 활동의 확대, 기존 바이러스 벡터 플랫폼의 채택 등에 기인한 것으로 추정됩니다.

바이러스 벡터 및 플라스미드 DNA 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 18억 9,000만 달러에 이르고, CAGR은 6.6%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 임상 등급 및 GMP 플라즈미드 DNA 개발, 암 및 감염성 질환 분야에서의 바이러스 벡터 적용 범위 확대, 유전자 치료에 대한 투자 증가, 면역 치료 솔루션에 대한 수요 증가, AAV 및 렌티바이러스 벡터와 같은 새로운 AAV, 렌티바이러스 벡터 등 신규 벡터 플랫폼의 채택 등을 들 수 있습니다. 예측 기간 동안 주요 동향으로는 유전자 치료에서 플라스미드 DNA 및 바이러스 벡터의 채택 증가, 암 및 유전성 질환 치료를 위한 바이러스 벡터 플랫폼의 확대, 임상 적용을 위한 GMP 등급 플라스미드 DNA 생산의 성장, 새로운 아데노부수체 및 바이러스 렌티바이러스 벡터의 연구 발전, 면역치료 및 백신 개발에서 플라스미드 DNA와 바이러스 벡터의 통합 등을 꼽을 수 있습니다.

결핵 발병률 증가는 향후 몇 년 동안 바이러스 벡터 및 플라스미드 DNA 시장의 성장을 견인할 것으로 예측됩니다. 결핵(TB)은 세균 감염에 의해 발생하는 전염성이 강한 심각한 전염병으로 주로 폐에 영향을 미치지만 신체의 다른 부위에도 영향을 미칠 수 있습니다. 플라스미드 DNA 백신은 결핵의 미생물 항원을 암호화하는 유전자를 주입하는 데 활용되어 왔습니다. 이 백신은 결핵의 원인균인 결핵균의 특정 항원을 발현하도록 설계할 수 있으며, 보통 근육 주사로 투여합니다. 예를 들어, 영국 정부 기관 GOV.UK에 따르면 2024년 2월 기준 영국 내 결핵 환자 수는 2023년 10.7% 증가하여 2022년 4,380명에서 4,850명으로 증가했다고 합니다. 그 결과, 결핵의 확산이 바이러스 벡터 및 플라스미드 DNA 시장의 성장에 기여하고 있습니다.

바이러스 벡터 및 플라스미드 DNA 시장에서 사업을 전개하는 주요 기업들은 경쟁 우위를 강화하기 위해 헬퍼 플라스미드와 같은 혁신적인 제품 출시에 집중하고 있습니다. 헬퍼 플라스미드는 유전자 치료 용도로 널리 사용되는 아데노부수체 바이러스 벡터(AAV)를 포함한 바이러스 벡터의 제조에 사용되는 플라스미드 DNA의 일종입니다. 예를 들어, 2023년 3월 미국 제약회사 찰스 리버 래버러토리스(Charles River Laboratories)는 기성품인 pHHelper 플라스미드를 출시하였습니다. 이 헬퍼 플라스미드는 AAV 기반 유전자 치료 프로그램에서 초기 발견 단계부터 상업적 생산에 이르는 과정을 가속화하는 동시에 공급의 안정성을 보장하도록 설계되었습니다. CDMO의 종합적인 제품 및 서비스 포트폴리오의 일환으로, 헬퍼 플라스미드는 세포 및 유전자 치료 워크플로우에서 바이러스 벡터 패키징을 지원하여 복잡한 공급망을 간소화하는 데 기여합니다. 유전자 치료에 일반적으로 사용되는 아데노부수체 바이러스 벡터는 헬퍼 플라스미드를 이용하여 제조됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Viral vectors are tools derived from viral genomes that have been transformed into plasmid-based technologies and modified for safety by removing several essential genes, with viral components separated in the process. In contrast, plasmid DNA refers to small, circular DNA molecules found in certain bacteria and other microorganisms. These molecules are physically separate from chromosomal DNA and are capable of independent replication.

The primary product types in viral vectors and plasmid DNA include plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that exists independently of a cell's chromosomal DNA and occurs naturally in bacterial cells as well as in some eukaryotes. Plasmid genes often provide genetic advantages to bacteria, such as antibiotic resistance. These technologies are applied in the treatment of infectious diseases, genetic disorders, cancer, and other conditions, and are used in gene and cancer therapies, viral infection treatments, immunotherapy, formulation development, and additional applications. The key end-use sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies.

Tariffs have impacted the viral vectors and plasmid DNA market by increasing costs of imported raw materials, bioreactors, and specialized lab equipment used in plasmid and viral vector production. Segments like GMP-grade plasmid DNA and adenoviral or lentiviral vectors are most affected, particularly in North America and Europe where imports are high. This has resulted in higher production costs and potential delays in research and clinical applications. On the positive side, tariffs have encouraged domestic manufacturing, investment in local production facilities, and innovation in cost-effective vector technologies.

The viral vectors and plasmid dna market research report is one of a series of new reports from The Business Research Company that provides viral vectors and plasmid dna market statistics, including viral vectors and plasmid dna industry global market size, regional shares, competitors with a viral vectors and plasmid dna market share, detailed viral vectors and plasmid dna market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors and plasmid dna industry. This viral vectors and plasmid dna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral vectors and plasmid dna market size has grown strongly in recent years. It will grow from $1.38 billion in 2025 to $1.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to limited availability of viral vectors, reliance on research-grade plasmid dna, increasing gene therapy pipelines, growing biopharmaceutical r&d activities, adoption of conventional viral vector platforms.

The viral vectors and plasmid dna market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of clinical-grade and gmp plasmid dna, expansion of viral vector applications in cancer and infectious diseases, rising investment in gene therapy, growing demand for immunotherapy solutions, adoption of novel vector platforms such as aav and lentiviral vectors. Major trends in the forecast period include rising adoption of plasmid dna and viral vectors in gene therapy, expansion of viral vector platforms for cancer and genetic disorder treatments, growth in gmp-grade plasmid dna production for clinical applications, increasing research on novel adeno-associated and lentiviral vectors, integration of plasmid dna and viral vectors in immunotherapy and vaccine development.

The rising incidence of tuberculosis is expected to drive the expansion of the viral vector and plasmid DNA market in the coming years. Tuberculosis (TB) is a contagious and potentially serious infectious disease caused by bacterial infection, primarily affecting the lungs, although it can also spread to other parts of the body. Plasmid DNA vaccines have been utilized to deliver genes that encode microbial antigens for tuberculosis. These vaccines can be engineered to express specific antigens of Mycobacterium tuberculosis, the bacterium responsible for TB, and are typically administered via intramuscular injection. For example, in February 2024, according to GOV.UK, a UK-based government department, tuberculosis cases in England rose by 10.7% in 2023, increasing from 4,380 cases in 2022 to 4,850 cases. As a result, the growing prevalence of tuberculosis is contributing to the growth of the viral vector and plasmid DNA market.

Leading companies operating in the viral vector and plasmid DNA market are increasingly focused on launching innovative products, such as helper plasmids, to strengthen their competitive position. Helper plasmids are a type of plasmid DNA used in the production of viral vectors, including adeno-associated viral vectors (AAV), which are widely employed in gene therapy applications. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced the off-the-shelf pHelper plasmid. This helper plasmid is designed to accelerate progress from early discovery to commercial manufacturing of AAV-based gene therapy programs while ensuring supply reliability. As part of a comprehensive portfolio of contract development and manufacturing organization (CDMO) products and services, helper plasmids support viral vector packaging in cell and gene therapy workflows and help simplify complex supply chains. Adeno-associated viral vectors, commonly used in gene therapy, are produced using helper plasmids.

In January 2023, Moderna Inc., a US-based pharmaceutical and biotechnology company, acquired OriCiro Genomics for $85 million. This acquisition is intended to accelerate Moderna's pipeline development by enhancing its capabilities in plasmid DNA synthesis and amplification, which are essential components in the production of messenger RNA (mRNA). OriCiro Genomics is a Japan-based genome technology company that specializes in the development and commercialization of cell-free systems for the assembly and amplification of circular DNA molecules, including plasmids and viral vectors.

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Кaneka Corporation, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the viral vectors and plasmid dna market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Viral Vectors And Plasmid DNA Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses viral vectors and plasmid dna market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for viral vectors and plasmid dna ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The viral vectors and plasmid dna market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Plasmid DNA; Viral Vectors
• 2) By Disease: Infectious Diseases; Genetic Disorders; Cancer; Other Diseases
• 3) By Application: Gene And Cancer Therapies; Viral Infections; Immunotherapy; Formulation Development; Other Applications
• 4) By End User: Research Institutes; Biopharmaceutical And Pharmaceutical Companies
• Subsegments:
• 1) By Plasmid DNA: Research-Grade Plasmid DNA; Clinical-Grade Plasmid DNA; GMP (Good Manufacturing Practice) Plasmid DNA
• 2) By Viral Vectors: Adenoviral Vectors; Lentiviral Vectors; AAV (Adeno-Associated Virus) Vectors; Retroviral Vectors; Vesicular Stomatitis Virus (VSV) Vectors
• Companies Mentioned: FUJIFILM Diosynth Biotechnologies; FinVector Vision Therapies; Lonza Group AG; Cobra Biologics and Pharmaceutical Services; Brammer Bio; Кaneka Corporation; Cell and Gene Therapy Catapult; VGXI Inc.; MassBiologics; Sanofi; Spark Therapeutics; UniQure NV; Thermo Fisher Scientific; VIROVEK; SIRION Biotech GmbH; ALDEVRON; Oxford BioMedica; PlasmidFactory GmbH & Co. KG; Biovian Oy; BioReliance Corporation; 4D Molecular Therapeutics; Renova Therapeutics; Shenzhen SiBiono GeneTech Co.; Vigene Biosciences Inc.; Novasep; Genzyme Corporation; Oxford Gene Technology; Richter-Helm; MolMed; Merck KGaA Inc.; Catalent Inc.; WuXi AppTec; GenScript Biotech Corporation; Eurogentec; Creative Biogene
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Viral Vectors And Plasmid DNA Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Viral Vectors And Plasmid DNA Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Viral Vectors And Plasmid DNA Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Viral Vectors And Plasmid DNA Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Plasmid Dna And Viral Vectors In Gene Therapy
  • 4.2.2 Expansion Of Viral Vector Platforms For Cancer And Genetic Disorder Treatments
  • 4.2.3 Growth In Gmp-Grade Plasmid Dna Production For Clinical Applications
  • 4.2.4 Increasing Research On Novel Adeno-Associated And Lentiviral Vectors
  • 4.2.5 Integration Of Plasmid Dna And Viral Vectors In Immunotherapy And Vaccine Development

5. Viral Vectors And Plasmid DNA Market Analysis Of End Use Industries

• 5.1 Research Institutes
• 5.2 Biopharmaceutical Companies
• 5.3 Pharmaceutical Companies
• 5.4 Gene Therapy Laboratories
• 5.5 Academic And Clinical Research Centers

6. Viral Vectors And Plasmid DNA Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Viral Vectors And Plasmid DNA Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Viral Vectors And Plasmid DNA PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Viral Vectors And Plasmid DNA Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Viral Vectors And Plasmid DNA Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Viral Vectors And Plasmid DNA Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Viral Vectors And Plasmid DNA Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Viral Vectors And Plasmid DNA Market Segmentation

• 9.1. Global Viral Vectors And Plasmid DNA Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Plasmid DNA, Viral Vectors
• 9.2. Global Viral Vectors And Plasmid DNA Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Infectious Diseases, Genetic Disorders, Cancer, Other Diseases
• 9.3. Global Viral Vectors And Plasmid DNA Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications
• 9.4. Global Viral Vectors And Plasmid DNA Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Research Institutes, Biopharmaceutical And Pharmaceutical Companies
• 9.5. Global Viral Vectors And Plasmid DNA Market, Sub-Segmentation Of Plasmid DNA, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA
• 9.6. Global Viral Vectors And Plasmid DNA Market, Sub-Segmentation Of Viral Vectors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

10. Viral Vectors And Plasmid DNA Market Regional And Country Analysis

• 10.1. Global Viral Vectors And Plasmid DNA Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Viral Vectors And Plasmid DNA Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Viral Vectors And Plasmid DNA Market

• 11.1. Asia-Pacific Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Viral Vectors And Plasmid DNA Market

• 12.1. China Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Viral Vectors And Plasmid DNA Market

• 13.1. India Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Viral Vectors And Plasmid DNA Market

• 14.1. Japan Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Viral Vectors And Plasmid DNA Market

• 15.1. Australia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Viral Vectors And Plasmid DNA Market

• 16.1. Indonesia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Viral Vectors And Plasmid DNA Market

• 17.1. South Korea Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Viral Vectors And Plasmid DNA Market

• 18.1. Taiwan Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Viral Vectors And Plasmid DNA Market

• 19.1. South East Asia Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Viral Vectors And Plasmid DNA Market

• 20.1. Western Europe Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Viral Vectors And Plasmid DNA Market

• 21.1. UK Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Viral Vectors And Plasmid DNA Market

• 22.1. Germany Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Viral Vectors And Plasmid DNA Market

• 23.1. France Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Viral Vectors And Plasmid DNA Market

• 24.1. Italy Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Viral Vectors And Plasmid DNA Market

• 25.1. Spain Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Viral Vectors And Plasmid DNA Market

• 26.1. Eastern Europe Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Viral Vectors And Plasmid DNA Market

• 27.1. Russia Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Viral Vectors And Plasmid DNA Market

• 28.1. North America Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Viral Vectors And Plasmid DNA Market

• 29.1. USA Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Viral Vectors And Plasmid DNA Market

• 30.1. Canada Viral Vectors And Plasmid DNA Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Viral Vectors And Plasmid DNA Market

• 31.1. South America Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Viral Vectors And Plasmid DNA Market

• 32.1. Brazil Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Viral Vectors And Plasmid DNA Market

• 33.1. Middle East Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Viral Vectors And Plasmid DNA Market

• 34.1. Africa Viral Vectors And Plasmid DNA Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Viral Vectors And Plasmid DNA Market, Segmentation By Product, Segmentation By Disease, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Viral Vectors And Plasmid DNA Market Regulatory and Investment Landscape

36. Viral Vectors And Plasmid DNA Market Competitive Landscape And Company Profiles

• 36.1. Viral Vectors And Plasmid DNA Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Viral Vectors And Plasmid DNA Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Viral Vectors And Plasmid DNA Market Company Profiles
  • 36.3.1. FUJIFILM Diosynth Biotechnologies Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. FinVector Vision Therapies Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Cobra Biologics and Pharmaceutical Services Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Brammer Bio Overview, Products and Services, Strategy and Financial Analysis

37. Viral Vectors And Plasmid DNA Market Other Major And Innovative Companies

• Кaneka Corporation, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation

38. Global Viral Vectors And Plasmid DNA Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Viral Vectors And Plasmid DNA Market

40. Viral Vectors And Plasmid DNA Market High Potential Countries, Segments and Strategies

• 40.1 Viral Vectors And Plasmid DNA Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Viral Vectors And Plasmid DNA Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Viral Vectors And Plasmid DNA Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer